Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus

Journal of Nuclear Medicine

Volumn 48, Issue 8, 2007, Pages 1251-1258

  Guo, Hongbo ^a   Zhu, Hui ^a   Xi, Yan ^b   Zhang, Baijiang ^a   Li, Ling ^a   Huang, Yong ^a   Zhang, Jiandong ^b   Fu, Zheng ^a   Yang, Guoren ^a   Yuan, Shuanghu ^a   Yu, Jinming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Esophageal squamous cell carcinoma; Gastroenterology; PET CT; Prognosis; Relapse

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ESOPHAGUS CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34547813068     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.036509     Document Type: Article

References (25)

1. Portale G, Hagen JA, Peters JH, et al. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg. 2006;202:588-596.
2. Altorki NK, Girardi L, Skinner DB. En bloc esophagectomy improves survival for stage III esophageal cancer. J Thorac Cardiovasc Surg. 1997;114:948-955.
3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-29.
4. Buenaventura P, Luketich JD. Surgical staging of esophageal cancer. Chest Surg Clin N Am. 2000;10:487-497.
5. Law SYK, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg. 1996;83:107-111.
6. Raoul JL, Le Prise E, Meunier B, et al. Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut. 1995;37:174-176.
7. Carlisle JG, Quint LE, Francis IR, Orringer MB, Smick JF, Gross BH. Recurrent esophageal carcinoma: CT evaluation after esophagectomy. Radiology. 1993;189:271-275.
8. Esteves FP, Schuster DM, Halkar RK. Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med. 2006;36:169-181.
9. Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Kuwano H. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg. 2004;91:1004-1009.
10. Flamen P, Lerut A, Van Cutsem E, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg. 2000;120:1085-1092.
11. Skehan SJ, Brown AL, Thompson M, Young JE, Coates G. Nahmias C. Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics. 2000;20:713-723.
12. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-1379.
13. Yuan S, Yu Y, Chao KS, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med. 2006;47:1255-1259.
14. 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? J Nucl Med. 2004;45:2045-2051.
15. 18F-FDG PET. J Nucl Med. 2004;45:980-987.
16. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224:748-756.
17. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in esophageal cancer: incremental value over computed tomography. Clin Positron Imaging. 1999;2:255-260.
18. 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998;19:1055-1063.
19. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285:914-924.
20. Pan T, Mawlawi O, Nehmeh SA, et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med. 2005;46:1481-1487.
21. Jadvar H, Henderson RW, Conti PS. 2-Deoxy-2-[F-18]fluoro-D-glucose- positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol. 2006;8:193-200.
22. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology. 1999;213:521-525.
23. Keyes JW Jr. SUV: Standard uptake or silly useless value? J Nucl Med. 1995;36:1836-1839.
24. Rizk N, Downey RJ, Akhurst T, et al. Preoperative 18[F]- fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg. 2006;81:1076-1081.
25. Blackstock AW, Farmer MR, Lovato J, et al. A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2006;64:455-460.